Jon_Earhart

Senior Genomic Specialist with Decipher Biosciences. Learning about Urology, Radiation Oncology, and Genomics on Twitter!

[Veracyte, Inc. @Veracyte]

This weekend's #ASCO26 sessions put a spotlight on key advances in urologic cancers. Here's a recap from a session, where Christopher Sweeney, M.B.B.S., Adelaide University, presented new data from the #ENZAMET phase 3 trial.

The talk explored whether the Decipher® Prostate Genomic Classifier can identify which patients with metastatic prostate cancer may benefit from adding the chemotherapy docetaxel to androgen deprivation therapy (ADT) plus enzalutamide (also known as triplet therapy), and which may safely avoid it.

| Primary Takeaway |

🔹 The #DecipherProstateTest identifies which metastatic prostate cancer patients may benefit from treatment intensification, and which can be safely spared chemotherapy, giving clinicians an actionable, evidence-based answer.

🔹 The ENZAMET findings build on prior validation in the STAMPEDE and CHAARTED trials, where Decipher Prostate identified patients most likely to benefit from adding docetaxel to ADT alone.

🔹 ENZAMET advances that evidence with the first demonstration that the test predicts chemotherapy benefit when added to doublet therapy (ADT plus an androgen receptor pathway inhibitor, like enzalutamide).

| Some Thank You's |

💙 We're grateful to Dr. Sweeney for sharing these important findings with the oncology community and for an ongoing commitment to improving care for the millions of men living with prostate cancer worldwide, including about 30,000 in the US who present with metastatic disease at diagnosis.(1,2)

💙 Thank you to everyone who joined the session and to the investigators, site teams, and participants whose contributions made this research possible.

| Additional Resources |

Learn more about the Decipher Prostate Genomic Classifier - https://t.co/6VCW4sx9ni

ENZAMET Trial Information - https://t.co/lNVWqagngG

STAMPEDE Trial Information - https://t.co/L8BeRIGLwU

CHAARTED Trial Information - https://t.co/iLkF5W8YOM

| References |

(1) https://t.co/Q5XE5pcH6e; https://t.co/IiAknUacvv

(2) https://t.co/XdMlZgAoet

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: https://t.co/fQcKkGFugi
#DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #ClinicalTrials #TeamVeracyte

[UroToday.com @urotoday]

NRG-GU006 trial for post-prostatectomy radiation therapy. @DrSpratticus @caseccc joins @jmmrad @WashUMedRadOnc to present the NRG GU006/BALANCE trial results, demonstrating PAM50 molecular subtypes as the first prospectively validated predictive biomarker guiding hormone therapy decisions in recurrent #ProstateCancer. #WatchNow on UroToday > https://t.co/s0VyiZcKy3 @Decipher_VCYT @NRGOncology

[AttardLab @AttardLab]

Excited to share our study Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancer @EmilyGrist1 @marina_parry @MRCCTU @uclcancer @ProstateUK @PCFnews @Prof_Nick_James @LotanLab @Decipher_VCYT @ChrisSweens1 https://t.co/0m3J71ThrZ

[Veracyte, Inc. @Veracyte]

NEW RESEARCH: Focal therapy is a treatment option for select patients with prostate cancer, yet ~20% experience early failure.

Our #DecipherProstate genomic classifier has been proposed as a more effective predictor of early recurrence compared to traditional clinical indicators.

| KEY FINDINGS |

In a pooled analysis of data from a phase II trial and a prospective cohort, higher Decipher scores were significantly associated with an increased risk of post-focal therapy recurrence.

This suggests Decipher's utility in identifying patients who may benefit more from: 
🔹 Radical treatment approaches  
🔹 Closer monitoring protocols   

🔗 Read the full article: https://t.co/NUFxZHcnSs     

#FocalTherapy #ProstateCancer #PrecisionMedicine #DecipherUrologicCancers #GenomicTesting #ClinicalResearch #UrologicOncology #PersonalizedMedicine #CancerTreatment

[Veracyte, Inc. @Veracyte]

Decipher® Prostate Metastatic test is now available in the U.S. for patients with metastatic prostate cancer.

Validated in over 90 peer-reviewed studies and 200K patients, this tissue-based test is a highly accurate predictor of:
🔹Metastatic progression
🔹 Prostate cancer-specific mortality
🔹 Overall survival

Read the press release: https://t.co/jJqAJZzkzY

Learn more about Decipher Prostate Metastatic test: https://t.co/cYBSoXb73M

Note: https://t.co/tltSRBtiSL

#DeciplerProstate #ProstateCancer #PrecisionMedicine #GenomicTesting #PersonalizedMedicine

[Andy Hanson @AndrewH11556067]

APCCC Diagnostics 2025: Risk Stratification Using a Genomic Classifier for Localized Prostate Cancer: What Is the Added Value? https://t.co/tfohE9dBSL

[UroToday.com @urotoday]

Biomarkers for gemcitabine docetaxel in non-muscle invasive #BladderCancer. @VigneshPackiam @RutgersCancer joins @JoepJdeJong @ErasmusMC to discuss promising results for non-muscle invasive bladder cancer, with potential biomarkers on the horizon for precision medicine. #WatchNow > https://t.co/XfoAV5MGie #NMIBC

[Andy Hanson @AndrewH11556067]

Treatment Intensification Strategies for High-Risk Prostate Cancer Patients - Aaron Berger https://t.co/uP1R78rT38

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Can the transcriptome reveal therapeutic vulnerabilities in localized #prostatecancer?🚨

👉Check out our analysis of >140k tumor samples in @EurUrolOncol

🔗https://t.co/Kxvhh5JXuI

[Decipher by Veracyte @Decipher_VCYT]

Join us at the Oregon Urological Society, in Sunriver, OR, from May 16-18. Stop by the #Decipher by @Veracyte booth to discuss how we are informing #ProstateCancer patient care. #UrologicCancer #PrecisionMedicine

[UroToday.com @urotoday]

Decipher score as a predictor of response to treatment intensification in the @NRGOncology-RTOG 0534 #SPPORT phase III randomized post-prostatectomy salvage radiotherapy trial. Presentation by @_APollack @SylvesterCancer. #GU25 written coverage by @RKSayyid @USC > https://t.co/kfbwmOsNzq @Decipher_VCYT

[UroToday.com @urotoday]

🔬 Personalizing Active Surveillance 🔬

Mark Sultan & Eric Kim discuss integrating Decipher® genomic scores and MRI findings to predict prostate cancer progression. Their research shows these tools provide complementary risk insights, guiding tailored surveillance protocols. Balancing data with patient preferences is key for smarter, patient-focused care decisions.
#WatchNow > https://t.co/wlJhv2nvrL @Decipher_VCYT #SUO24

[UroToday.com @urotoday]

Utilizing the #Decipher mRNA score for risk stratification in #mHSPC. David Morris, MD, FACS @UA_Nashville and @ashleyrossmdphd @NUFeinbergMed discuss how Decipher can help stratify patients and guide treatment decisions. Full video > https://t.co/NbKWmpdQQZ @Decipher_VCYT

[UroToday.com @urotoday]

#Decipher mRNA score for prediction of survival benefit from docetaxel at start of ADT for advanced #ProstateCancer: an ancillary study of the #STAMPEDE docetaxel trials. Presented by @EmilyGrist1 @royalmarsdenNHS. #ESMO24 written coverage by @RKSayyid > https://t.co/KnZtImEb5f

[Decipher by Veracyte @Decipher_VCYT]

Save the date! @Veracyte's #Decipher Team will be at the Washington State Urology Society Annual Conference, in Stevenson, WA on June 21-23. Stop by our booth to discuss how we are changing #ProstateCancer patient care.

[Decipher by Veracyte @Decipher_VCYT]

Save the date! @Veracyte's #Decipher Team will be at the Oregon Urological Society meeting in Sunriver, OR, on June 7-9. Stop by our booth to discuss how we are changing #ProstateCancer patient care.

[Decipher by Veracyte @Decipher_VCYT]

We will be attending the Society of Urologic Oncology meeting it will be taking place on November 28th - December 1st 2023 in Washington, DC!

Visit our booth & learn how @Veracyte's Decipher Prostate GC can help men living with #ProstateCancer

[Zach Klaassen @zklaassen_md]

Cross-Comparison IPD Analysis of Three Gene Expression Signatures in Localized #prostatecancer in >50,000 Men #ASTRO23 @a@angela_jia_ @urotoday

📌 15,379 NCCN low-risk, 14,773 fav int-risk, 15,544 unfav int-risk, and 5,185 high/very high-risk
📌 Oncotype model had poor goodness-of-fit to the 22-gene Decipher GC: R2 = 0.36
📌 Prolaris model had poor goodness-of-fit to the 22-gene Decipher GC: R2 = 0.32
📌 ~60% of information from the Decipher GC is unique and not explained by known variables
📌 These tests should not be viewed as interchangeable

[UroToday.com @urotoday]

Risk assessment in localized #ProstateCancer - Insights from real-world data and SEER registry. @jimhumd @WeillCornell joins @ashleyrossmdphd @NM_Urology to discuss the use of genomic classifiers in the mgmt of localized PCa on UroToday > https://t.co/0qXTiUwC1m @Decipher_VCYT

[Decipher by Veracyte @Decipher_VCYT]

ICYMI: New data from a post-hoc analysis of the phase 3 RCT RTOG 0126 trial was published in @IJROBP & further validates the clinical utility of @Veracyte's #Decipher Prostate in guiding patient management in the definitive radiotherapy setting. Read here: https://t.co/A5b51RPubc